Drug Profile


Alternative Names: GTx-024; MK-2866; Ostarine

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator GTx
  • Class Nitriles; Small molecules
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cachexia

Highest Development Phases

  • Phase II Breast cancer; Stress incontinence
  • Preclinical Duchenne muscular dystrophy
  • Discontinued Cachexia; Muscular atrophy

Most Recent Events

  • 01 Mar 2017 GTx completes a phase II trial in estrogen receptor-positive Breast cancer (Metastatic disease) in USA (PO) (NCT01616758)
  • 26 Jan 2017 Cancer Research UK and University of Liverpool plan the phase II EMERALD trial for Breast cancer (Early-stage disease) in United Kingdom (PO, Capsule) (ISRCTN12213700)
  • 08 Dec 2016 Inital safety and efficacy data from phase II trial in Breast cancer released by GTx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top